{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:42:27Z","timestamp":1791052947055,"version":"4.1.0"},"reference-count":490,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>The classic Philadelphia chromosome\u2013negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.<\/jats:p>","DOI":"10.6004\/jnccn.2022.0046","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T19:38:00Z","timestamp":1662665880000},"page":"1033-1062","source":"Crossref","is-referenced-by-count":122,"title":["Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"20","author":[{"given":"Aaron T.","family":"Gerds","sequence":"first","affiliation":[{"name":"1Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"2Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"3City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"4The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dunbar","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Elshoury","sequence":"additional","affiliation":[{"name":"6Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"7Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[{"name":"8Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"9Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"10Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[{"name":"12UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Kaesberg","sequence":"additional","affiliation":[{"name":"13UC Davis Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"14Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Madanat","sequence":"additional","affiliation":[{"name":"15UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McMahon","sequence":"additional","affiliation":[{"name":"16University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Mohan","sequence":"additional","affiliation":[{"name":"17Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan V.","family":"Nadiminti","sequence":"additional","affiliation":[{"name":"18University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Oh","sequence":"additional","affiliation":[{"name":"19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"20Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"21Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Rein","sequence":"additional","affiliation":[{"name":"22Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Salit","sequence":"additional","affiliation":[{"name":"23Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady L.","family":"Stein","sequence":"additional","affiliation":[{"name":"24Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"25University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"26O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"27Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wall","sequence":"additional","affiliation":[{"name":"28The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Ward","sequence":"additional","affiliation":[{"name":"29UCLA Jonsson Comprehensive Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Bergman","sequence":"additional","affiliation":[{"name":"30National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hochstetler","sequence":"additional","affiliation":[{"name":"30National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref4261","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbmt.2020.03.007","article-title":"Targeted sequencing improves DIPSS-Plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation","volume":"26","author":"Stevens","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3461","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"ref3411","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"ref2771","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"ref2191","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127859","article-title":"Updated results from the German Mpnsg-0212 combination trial: ruxolitinib plus pomalidomide in myelofibrosis with anemia [abstract]","volume":"134","author":"Stegelmann","year":"2019","journal-title":"Blood"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-8722-6-79","article-title":"Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing","volume":"6","author":"Mesa","year":"2013","journal-title":"J Hematol Oncol"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"ref3721","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"Am J Hematol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"ref4761","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref4031","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4361","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-8722-6-79","article-title":"Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing","volume":"6","author":"Mesa","year":"2013","journal-title":"J Hematol Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4481","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N Engl J Med"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref4741","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","article-title":"The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis","volume":"4","author":"McMullin","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"key":"ref3521","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"ref4691","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"key":"ref3031","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS- pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"ref2921","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS- pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"ref3501","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br J Haematol"},{"key":"ref3621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"ref4191","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"ref2681","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref4281","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"ref3431","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"key":"ref2951","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"ref4711","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study [abstract]","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref1391","first-page":"4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib [abstract]","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3201","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"ref3161","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref3211","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4221","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br J Haematol"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"key":"ref2991","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: Integrating morphological, clinical, and genomic data [published online June 29, 2022]","author":"Arber","journal-title":"Blood"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref3051","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjh.14838","article-title":"Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons","volume":"182","author":"Mudireddy","year":"2018","journal-title":"Br J Haematol"},{"key":"ref3481","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4651","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"424","DOI":"10.6004\/jnccn.2015.0058","article-title":"Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms","volume":"13","author":"Stein","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref3271","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref3191","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/10428194.2017.1365852","article-title":"MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients","volume":"59","author":"ElNahass","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref4331","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","journal-title":"Leuk Res"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"ref4861","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","article-title":"Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia","volume":"13","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"key":"ref3811","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"ref3441","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbmt.2020.03.007","article-title":"Targeted sequencing improves DIPSS-Plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation","volume":"26","author":"Stevens","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3681","first-page":"284168","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump","volume":"2015","author":"Shamil","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br J Haematol"},{"key":"ref3041","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"Am J Hematol"},{"key":"ref3281","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","article-title":"Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts","volume":"6","author":"Talpaz","year":"2013","journal-title":"J Hematol Oncol"},{"key":"ref3531","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol Oncol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"ref2791","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"ref4571","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","article-title":"Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"19","author":"Merup","year":"2002","journal-title":"Med Oncol"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","article-title":"AML transformation in 56 patients with Ph- MPD in two well defined populations","volume":"82","author":"Abdulkarim","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref2181","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study [abstract]","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"key":"ref3691","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N Engl J Med"},{"key":"ref561","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"key":"ref2901","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"ref3551","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3731","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428190802713521","article-title":"Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience","volume":"50","author":"Palandri","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref3761","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.leukres.2015.05.002","article-title":"Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome","volume":"39","author":"Masarova","year":"2015","journal-title":"Leuk Res"},{"key":"ref4051","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"key":"ref4111","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"key":"ref4511","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br J Haematol"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi","year":"2019","journal-title":"Am J Hematol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref3641","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref3891","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000 Res"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000 Res"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref3241","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0037-1614018","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"key":"ref4811","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","article-title":"AML transformation in 56 patients with Ph- MPD in two well defined populations","volume":"82","author":"Abdulkarim","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref3831","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-018-0152-x","article-title":"Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea","volume":"8","author":"Pacilli","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"848473","DOI":"10.1155\/2015\/848473","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","volume":"2015","author":"Davis","year":"2015","journal-title":"Adv Hematol"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Leukemia"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"ref4021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","article-title":"The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis","volume":"4","author":"McMullin","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref4931","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"key":"ref5031","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1658.1658","article-title":"Pacritinib (PAC) synergistically potentiates azacitidine (5AZA) cytotoxicity in chronic myelomonocytic leukemia (CMML) [abstract]","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2501","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1658.1658","article-title":"Pacritinib (PAC) synergistically potentiates azacitidine (5AZA) cytotoxicity in chronic myelomonocytic leukemia (CMML) [abstract]","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"},{"key":"ref5001","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"key":"ref3821","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"key":"ref4411","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref4461","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"ref2911","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"key":"ref2961","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.leukres.2008.04.022","article-title":"Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases","volume":"32","author":"Santana-Davila","year":"2008","journal-title":"Leuk Res"},{"key":"ref3701","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"key":"ref4521","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000097463","article-title":"Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis","volume":"117","author":"Tsiara","year":"2007","journal-title":"Acta Haematol"},{"key":"ref3381","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","article-title":"Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis","volume":"54","author":"Jain","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"ref3261","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref3791","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi","year":"2019","journal-title":"Am J Hematol"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref4501","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-139086","article-title":"Real world risk of splenic rupture with G-CSF\/GM-CSF therapy: a pharmacovigilance assessment using FDA Adverse Event Reporting System (FAERS) database [abstract]","volume":"136","author":"Kaur","year":"2020","journal-title":"Blood"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"ref4151","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"key":"ref3921","first-page":"4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib [abstract]","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/10428194.2017.1365852","article-title":"MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients","volume":"59","author":"ElNahass","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"key":"ref2981","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref4391","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring MplW515L\/K mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-018-0152-x","article-title":"Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea","volume":"8","author":"Pacilli","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref4561","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"ref3081","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"ref3991","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2009.09.020","article-title":"Improved outcomes using tacrolimus\/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis","volume":"16","author":"Snyder","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4181","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-018-3240-x","article-title":"Prognostic risk models for transplant decision-making in myelofibrosis","volume":"97","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Ann Hematol"},{"key":"ref571","first-page":"101","article-title":"Thrombotic and bleeding complications in classical myeloproliferative neoplasms","volume":"39","author":"McMahon","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"ref3961","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbmt.2006.06.014","article-title":"Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis","volume":"12","author":"Snyder","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.0902-4441.2003.00188.x","article-title":"Thalidomide for the treatment of idiopathic myelofibrosis","volume":"72","author":"Strupp","year":"2004","journal-title":"Eur J Haematol"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-018-3240-x","article-title":"Prognostic risk models for transplant decision-making in myelofibrosis","volume":"97","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Ann Hematol"},{"key":"ref3751","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref4971","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"key":"ref4321","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref4831","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","journal-title":"Leuk Res"},{"key":"ref4611","first-page":"1027","article-title":"Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study","volume":"91","author":"Abgrall","year":"2006","journal-title":"Haematologica"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbmt.2006.06.014","article-title":"Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis","volume":"12","author":"Snyder","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4591","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.0902-4441.2003.00188.x","article-title":"Thalidomide for the treatment of idiopathic myelofibrosis","volume":"72","author":"Strupp","year":"2004","journal-title":"Eur J Haematol"},{"key":"ref2931","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"ref2201","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"ref3421","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Cris\u00e0","year":"2018","journal-title":"Br J Haematol"},{"key":"ref4911","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref3231","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"ref4891","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"key":"ref3631","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"ref3141","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3221","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"ref3251","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref4531","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"key":"ref3101","first-page":"101","article-title":"Thrombotic and bleeding complications in classical myeloproliferative neoplasms","volume":"39","author":"McMahon","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"ref4671","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.leukres.2008.04.022","article-title":"Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases","volume":"32","author":"Santana-Davila","year":"2008","journal-title":"Leuk Res"},{"key":"ref3671","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref3741","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref4431","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref4101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Leukemia"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-007-0090-0","article-title":"Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma","volume":"26","author":"Lippi","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo- controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"ref3711","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen","year":"2014","journal-title":"Ann Hematol"},{"key":"ref4441","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"ref2801","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"key":"ref2611","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref2811","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref3071","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"key":"ref4701","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref4801","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clml.2020.12.024","article-title":"Clinical significance of bone marrow blast percentage in patients with myelofibrosis and the effect of ruxolitinib therapy","volume":"21","author":"Masarova","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref5011","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"ref451","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref4681","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref3781","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"ref3391","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"key":"ref4351","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"ref4981","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ajh.24098","article-title":"Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls","volume":"90","author":"Anderson","year":"2015","journal-title":"Am J Hematol"},{"key":"ref2011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7002","article-title":"MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor [abstract]","volume":"40","author":"Mesa","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","article-title":"Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN)","volume":"9","author":"Price","year":"2014","journal-title":"PLoS One"},{"key":"ref4001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref4951","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"ref2941","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"key":"ref3581","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref2871","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref4251","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.13318","article-title":"Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation","volume":"103","author":"Mannina","year":"2019","journal-title":"Eur J Haematol"},{"key":"ref4781","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref5051","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-139086","article-title":"Real world risk of splenic rupture with G-CSF\/GM-CSF therapy: a pharmacovigilance assessment using FDA Adverse Event Reporting System (FAERS) database [abstract]","volume":"136","author":"Kaur","year":"2020","journal-title":"Blood"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref3661","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"424","DOI":"10.6004\/jnccn.2015.0058","article-title":"Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms","volume":"13","author":"Stein","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjh.14838","article-title":"Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons","volume":"182","author":"Mudireddy","year":"2018","journal-title":"Br J Haematol"},{"key":"ref4451","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"ref3451","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"ref3971","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced- intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3361","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"ref3171","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"key":"ref4791","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref3911","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2021-147607","article-title":"Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus knase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): Results from the phase 3b FREEDOM trial [abstract]","volume":"138","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"ref4141","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.clml.2022.01.003","article-title":"The effect of fedratinib, a selective inhibitor of janus kinase 2, on weight and metabolic parameters in patients with intermediate- or high-risk myelofibrosis","volume":"22","author":"Tremblay","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4041","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","article-title":"Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis","volume":"54","author":"Jain","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.06.007","article-title":"Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis","volume":"48","author":"Chihara","year":"2016","journal-title":"Leuk Res"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"e2010010","DOI":"10.4084\/mjhid.2010.010","article-title":"Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience","volume":"2","author":"Patriarca","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref4551","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10637-019-00786-4","article-title":"Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2\/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML","volume":"38","author":"Jeon","year":"2020","journal-title":"Invest New Drugs"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref4341","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","article-title":"Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts","volume":"6","author":"Talpaz","year":"2013","journal-title":"J Hematol Oncol"},{"key":"ref4771","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref461","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: Integrating morphological, clinical, and genomic data [published online June 29, 2022]","author":"Arber","journal-title":"Blood"},{"key":"ref2861","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"ref2081","first-page":"1027","article-title":"Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study","volume":"91","author":"Abgrall","year":"2006","journal-title":"Haematologica"},{"key":"ref4941","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4271","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"key":"ref4081","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3061","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"ref2841","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br J Haematol"},{"key":"ref2821","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring MplW515L\/K mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"ref4851","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res"},{"key":"ref2891","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref3341","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"ref3611","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"ref4241","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000097463","article-title":"Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis","volume":"117","author":"Tsiara","year":"2007","journal-title":"Acta Haematol"},{"key":"ref4841","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"ref4301","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4401","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"ref3901","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","article-title":"Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival","volume":"84","author":"Patnaik","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.13318","article-title":"Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation","volume":"103","author":"Mannina","year":"2019","journal-title":"Eur J Haematol"},{"key":"ref3861","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br J Haematol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref3871","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref941","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a multi-center Bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis [abstract]","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"key":"ref3181","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res"},{"key":"ref4061","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref4721","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127859","article-title":"Updated results from the German Mpnsg-0212 combination trial: ruxolitinib plus pomalidomide in myelofibrosis with anemia [abstract]","volume":"134","author":"Stegelmann","year":"2019","journal-title":"Blood"},{"key":"ref3881","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.clml.2022.01.003","article-title":"The effect of fedratinib, a selective inhibitor of janus kinase 2, on weight and metabolic parameters in patients with intermediate- or high-risk myelofibrosis","volume":"22","author":"Tremblay","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"key":"ref4961","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref3771","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"key":"ref3561","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref3571","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"ref3111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"key":"ref2761","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref5021","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10637-019-00786-4","article-title":"Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2\/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML","volume":"38","author":"Jeon","year":"2020","journal-title":"Invest New Drugs"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","article-title":"Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups","volume":"21","author":"Deeg","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4541","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7002","article-title":"MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor [abstract]","volume":"40","author":"Mesa","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref2971","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.25335","article-title":"Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am J Hematol"},{"key":"ref4871","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"ref2781","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3401","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.25335","article-title":"Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am J Hematol"},{"key":"ref1151","first-page":"284168","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump","volume":"2015","author":"Shamil","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"ref4991","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/busulfan conditioning-based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4921","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","article-title":"Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"19","author":"Merup","year":"2002","journal-title":"Med Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref3471","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a multi-center Bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis [abstract]","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"key":"ref3121","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0037-1614018","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref3541","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref4161","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2021-147607","article-title":"Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus knase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): Results from the phase 3b FREEDOM trial [abstract]","volume":"138","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"key":"ref3511","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"ref3591","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"ref4661","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.06.007","article-title":"Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis","volume":"48","author":"Chihara","year":"2016","journal-title":"Leuk Res"},{"key":"ref4901","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428190802713521","article-title":"Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience","volume":"50","author":"Palandri","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref4381","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"ref2711","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"ref3651","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the myelofibrosis transplant scoring system (MTSS) and development of a new prognostic model","volume":"26","author":"Hern\u00e1ndez-Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3291","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref4751","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Cris\u00e0","year":"2018","journal-title":"Br J Haematol"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","article-title":"Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia","volume":"13","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"ref3301","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref4231","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref5041","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"ref4471","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"ref4211","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"ref3001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref2601","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"ref2741","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"ref3981","doi-asserted-by":"crossref","first-page":"e2010010","DOI":"10.4084\/mjhid.2010.010","article-title":"Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience","volume":"2","author":"Patriarca","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","article-title":"Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN)","volume":"9","author":"Price","year":"2014","journal-title":"PLoS One"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4071","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","article-title":"Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups","volume":"21","author":"Deeg","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4121","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"ref2831","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref4421","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"key":"ref3941","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref3801","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref2851","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref4631","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref3091","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"ref3151","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and Karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref3371","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clml.2020.12.024","article-title":"Clinical significance of bone marrow blast percentage in patients with myelofibrosis and the effect of ruxolitinib therapy","volume":"21","author":"Masarova","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3951","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced- intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3021","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref4171","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2009.09.020","article-title":"Improved outcomes using tacrolimus\/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis","volume":"16","author":"Snyder","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1191","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"ref3311","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ajh.24098","article-title":"Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls","volume":"90","author":"Anderson","year":"2015","journal-title":"Am J Hematol"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4291","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/busulfan conditioning-based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4091","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4201","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the myelofibrosis transplant scoring system (MTSS) and development of a new prognostic model","volume":"26","author":"Hern\u00e1ndez-Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4581","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.leukres.2015.05.002","article-title":"Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome","volume":"39","author":"Masarova","year":"2015","journal-title":"Leuk Res"},{"key":"ref4311","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4821","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen","year":"2014","journal-title":"Ann Hematol"},{"key":"ref4881","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"ref3841","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref3321","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"ref4621","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"ref3131","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-007-0090-0","article-title":"Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma","volume":"26","author":"Lippi","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"ref3491","doi-asserted-by":"crossref","first-page":"848473","DOI":"10.1155\/2015\/848473","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","volume":"2015","author":"Davis","year":"2015","journal-title":"Adv Hematol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"ref3331","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and Karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"key":"ref3601","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"ref2881","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref4731","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"ref4641","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref4601","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/9\/article-p1033.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/9\/article-p1033.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T19:10:37Z","timestamp":1701025837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/9\/article-p1033.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":490,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.0046","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}